ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN is extremely Undervalued

<< Previous

Bullboard Posts

Next >>

Post by DavidKingCanadaon Aug 31, 2021 8:22am

174 Views

Post# 33786881

PMN is extremely Undervalued

At a SP of less than 0.20 CAD it is a great time to stock up and wait a couple
of Months or maybe a Year or two. If you have room in your TFSA, Invest a few Thousand and you will thank us later!

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property